FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113338003> ?p ?o ?g. }

• W2113338003 endingPage "10" @default.
• W2113338003 startingPage "1" @default.
• W2113338003 abstract "Standard treatment for glioblastoma comprises surgical resection, chemotherapy with temozolomide, and radiotherapy. Nevertheless, majority of glioblastoma patients have recurrence from resistance to the cytotoxic conventional therapies. We examined combinational effects of KML001, an arsenic compound targeting telomeres of chromosomes with temozolomide or irradiation, in glioblastoma cell lines and xenograft models, to overcome the therapeutic limitation of chemoradiation therapy for glioblastoma. Although KML001 alone showed little effects on in vitro survival of glioblastoma cells, cell death by in vitro temozolomide treatment or irradiation was synergistically potentiated by combination with KML001. Since phosphorylated γ -H2AX, cleaved casepase-3, and cleaved PARP were dramatically increased by KML001, the synergistic effects would be mediated by increased DNA damage and subsequent tumor cell apoptosis. Combinatorial effects of KML001 were observed not only in chemo- and radiosensitive glioblastoma cell line, U87MG, but also in the resistant cell line, U251MG. In the U87MG glioblastoma xenograft models, KML001 did not have systemic toxicity but showed synergistic therapeutic effects in combination with temozolomide or irradiation to reduce tumor volumes significantly. These data indicated that KML001 could be a candidate sensitizer to potentiate therapeutic effects of conventional cytotoxic treatment for glioblastoma." @default.
• W2113338003 created "2016-06-24" @default.
• W2113338003 creator A5005664225 @default.
• W2113338003 creator A5008186343 @default.
• W2113338003 creator A5016984693 @default.
• W2113338003 creator A5018929039 @default.
• W2113338003 creator A5032643257 @default.
• W2113338003 creator A5041577954 @default.
• W2113338003 creator A5045186173 @default.
• W2113338003 creator A5077115592 @default.
• W2113338003 date "2014-01-01" @default.
• W2113338003 modified "2023-10-18" @default.
• W2113338003 title "KML001, a Telomere-Targeting Drug, Sensitizes Glioblastoma Cells to Temozolomide Chemotherapy and Radiotherapy through DNA Damage and Apoptosis" @default.
• W2113338003 cites W1967114760 @default.
• W2113338003 cites W1972546051 @default.
• W2113338003 cites W1976385056 @default.
• W2113338003 cites W1989187489 @default.
• W2113338003 cites W1990631589 @default.
• W2113338003 cites W1997158004 @default.
• W2113338003 cites W1999028431 @default.
• W2113338003 cites W2008162481 @default.
• W2113338003 cites W2009246149 @default.
• W2113338003 cites W2020812892 @default.
• W2113338003 cites W2026402231 @default.
• W2113338003 cites W2029825713 @default.
• W2113338003 cites W2039687515 @default.
• W2113338003 cites W2049012568 @default.
• W2113338003 cites W2049351453 @default.
• W2113338003 cites W2059948085 @default.
• W2113338003 cites W2104645911 @default.
• W2113338003 cites W2116508133 @default.
• W2113338003 cites W2118731052 @default.
• W2113338003 cites W2122620029 @default.
• W2113338003 cites W2127326807 @default.
• W2113338003 cites W2130926378 @default.
• W2113338003 cites W2132834292 @default.
• W2113338003 cites W2145200068 @default.
• W2113338003 cites W2145517527 @default.
• W2113338003 cites W2146232557 @default.
• W2113338003 cites W2147129352 @default.
• W2113338003 cites W2151847780 @default.
• W2113338003 cites W2161892620 @default.
• W2113338003 cites W2325707043 @default.
• W2113338003 doi "https://doi.org/10.1155/2014/747415" @default.
• W2113338003 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4176651" @default.
• W2113338003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25295271" @default.
• W2113338003 hasPublicationYear "2014" @default.
• W2113338003 type Work @default.
• W2113338003 sameAs 2113338003 @default.
• W2113338003 citedByCount "21" @default.
• W2113338003 countsByYear W21133380032013 @default.
• W2113338003 countsByYear W21133380032015 @default.
• W2113338003 countsByYear W21133380032016 @default.
• W2113338003 countsByYear W21133380032017 @default.
• W2113338003 countsByYear W21133380032018 @default.
• W2113338003 countsByYear W21133380032019 @default.
• W2113338003 countsByYear W21133380032020 @default.
• W2113338003 countsByYear W21133380032021 @default.
• W2113338003 countsByYear W21133380032022 @default.
• W2113338003 crossrefType "journal-article" @default.
• W2113338003 hasAuthorship W2113338003A5005664225 @default.
• W2113338003 hasAuthorship W2113338003A5008186343 @default.
• W2113338003 hasAuthorship W2113338003A5016984693 @default.
• W2113338003 hasAuthorship W2113338003A5018929039 @default.
• W2113338003 hasAuthorship W2113338003A5032643257 @default.
• W2113338003 hasAuthorship W2113338003A5041577954 @default.
• W2113338003 hasAuthorship W2113338003A5045186173 @default.
• W2113338003 hasAuthorship W2113338003A5077115592 @default.
• W2113338003 hasBestOaLocation W21133380031 @default.
• W2113338003 hasConcept C126322002 @default.
• W2113338003 hasConcept C134935766 @default.
• W2113338003 hasConcept C143425029 @default.
• W2113338003 hasConcept C154317977 @default.
• W2113338003 hasConcept C185592680 @default.
• W2113338003 hasConcept C190283241 @default.
• W2113338003 hasConcept C202751555 @default.
• W2113338003 hasConcept C2776194525 @default.
• W2113338003 hasConcept C2776694085 @default.
• W2113338003 hasConcept C2777389519 @default.
• W2113338003 hasConcept C31573885 @default.
• W2113338003 hasConcept C502942594 @default.
• W2113338003 hasConcept C509974204 @default.
• W2113338003 hasConcept C552990157 @default.
• W2113338003 hasConcept C55493867 @default.
• W2113338003 hasConcept C71924100 @default.
• W2113338003 hasConceptScore W2113338003C126322002 @default.
• W2113338003 hasConceptScore W2113338003C134935766 @default.
• W2113338003 hasConceptScore W2113338003C143425029 @default.
• W2113338003 hasConceptScore W2113338003C154317977 @default.
• W2113338003 hasConceptScore W2113338003C185592680 @default.
• W2113338003 hasConceptScore W2113338003C190283241 @default.
• W2113338003 hasConceptScore W2113338003C202751555 @default.
• W2113338003 hasConceptScore W2113338003C2776194525 @default.
• W2113338003 hasConceptScore W2113338003C2776694085 @default.
• W2113338003 hasConceptScore W2113338003C2777389519 @default.
• W2113338003 hasConceptScore W2113338003C31573885 @default.
• W2113338003 hasConceptScore W2113338003C502942594 @default.
• W2113338003 hasConceptScore W2113338003C509974204 @default.

• next